Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design.

Autoria(s): Hsieh, W.; Peh, B.K.; Loh, T.; Chiao, J.H.; Soo, R.; Cui, C.Y.; Green, S.R.; Lai, Y.F.; Salto-Tellez, Manuel; Mow, B.; Goh, B.C.
Data(s)

01/11/2005
Identificador

http://pure.qub.ac.uk/portal/en/publications/pharmacodynamic-effects-of-seliciclib-rroscovitine-cyc202-in-patients-with-undifferentiated-nasopharyngeal-carcinoma-npc-using-a-window-trial-design(bed8c7d8-6959-4f07-8340-04ff9ef4b69d).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Hsieh , W , Peh , B K , Loh , T , Chiao , J H , Soo , R , Cui , C Y , Green , S R , Lai , Y F , Salto-Tellez , M , Mow , B & Goh , B C 2005 , ' Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design. ' Clinical Cancer Research , vol 11 , pp. 8983S-8984S .
Tipo

article
Acesso ao item digital